How much revenue did Nanobiotix generate this year?
Nanobiotix has achieved a revenue of 28.85 M EUR this year.
Nanobiotix Revenue 2024
Nanobiotix Revenue
28.85 M EUR
Ticker
NANO.PA
ISIN
FR0011341205
WKN
A1J7EB
In 2024, Nanobiotix's sales reached 28.85 M EUR, a -4.02% difference from the 30.06 M EUR sales recorded in the previous year.
The Nanobiotix Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 159.4 | 3,00 |
| 2028e | 58.61 | 8,16 |
| 2027e | 30.12 | 15,87 |
| 2026e | 46.36 | 10,31 |
| 2025e | 17.79 | 26,87 |
| 2024e | 28.85 | 16,57 |
| 2023 | 30.06 | 15,90 |
| 2022 | - | - |
| 2021 | 0.01 | 26500,00 |
| 2020 | 0.05 | 4640,00 |
| 2019 | 0.07 | 7029,41 |
| 2018 | 0.12 | 4120,69 |
| 2017 | 0.25 | 1896,83 |
| 2016 | 1.56 | 306,78 |
| 2015 | 0.27 | 1800,11 |
| 2014 | 0.97 | 494,06 |
| 2013 | 0.18 | 2655,56 |
| 2012 | 0.07 | 6828,57 |
| 2011 | 1.36 | 100,00 |
| 2010 | 1.13 | 100,00 |
| 2009 | 2.77 | 96,39 |
Nanobiotix Revenue, EBIT, Net Income FR0011341205 · A1J7EB
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Nanobiotix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nanobiotix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nanobiotix’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Nanobiotix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Nanobiotix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Nanobiotix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nanobiotix’s growth potential.
Nanobiotix Revenue, EBIT and net profit per share
| Date | Nanobiotix Revenue | Nanobiotix EBIT | Nanobiotix Net Income |
|---|---|---|---|
| 2029e | 159.4 M undefined | 0 undefined | 70.49 M undefined |
| 2028e | 58.61 M undefined | -12.25 M undefined | -26.25 M undefined |
| 2027e | 30.12 M undefined | -38.38 M undefined | -43.27 M undefined |
| 2026e | 46.36 M undefined | -18.54 M undefined | -26.75 M undefined |
| 2025e | 17.79 M undefined | -48.96 M undefined | -49.17 M undefined |
| 2024e | 28.85 M undefined | -38.14 M undefined | -41.97 M undefined |
| 2023 | 30.06 M undefined | -26.78 M undefined | -39.7 M undefined |
| 2022 | 0 undefined | -46.7 M undefined | -57.04 M undefined |
| 2021 | 10,000 undefined | -52.58 M undefined | -47 M undefined |
| 2020 | 50,000 undefined | -36.43 M undefined | -33.59 M undefined |
| 2019 | 68,000 undefined | -46.78 M undefined | -50.92 M undefined |
| 2018 | 116,000 undefined | -30.07 M undefined | -30.35 M undefined |
| 2017 | 252,000 undefined | -25.27 M undefined | -26.14 M undefined |
| 2016 | 1.56 M undefined | -21.85 M undefined | -21.88 M undefined |
| 2015 | 265,540 undefined | -17.14 M undefined | -17 M undefined |
| 2014 | 967,500 undefined | -9.62 M undefined | -9.56 M undefined |
| 2013 | 180,000 undefined | -8.18 M undefined | -8.14 M undefined |
| 2012 | 70,000 undefined | -5.15 M undefined | -5.33 M undefined |
| 2011 | 1.36 M undefined | -5.23 M undefined | -5.25 M undefined |
| 2010 | 1.13 M undefined | -4.1 M undefined | -4.09 M undefined |
| 2009 | 2.77 M undefined | -1.5 M undefined | -1.51 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2009 | 2.77 M EUR | -1.5 M EUR | -1.51 M EUR |
| 2010 | 1.13 M EUR | -4.1 M EUR | -4.09 M EUR |
| 2011 | 1.36 M EUR | -5.23 M EUR | -5.25 M EUR |
| 2012 | 70,000 EUR | -5.15 M EUR | -5.33 M EUR |
| 2013 | 180,000 EUR | -8.18 M EUR | -8.14 M EUR |
| 2014 | 967,500 EUR | -9.62 M EUR | -9.56 M EUR |
| 2015 | 265,540 EUR | -17.14 M EUR | -17 M EUR |
| 2016 | 1.56 M EUR | -21.85 M EUR | -21.88 M EUR |
| 2017 | 252,000 EUR | -25.27 M EUR | -26.14 M EUR |
| 2018 | 116,000 EUR | -30.07 M EUR | -30.35 M EUR |
| 2019 | 68,000 EUR | -46.78 M EUR | -50.92 M EUR |
| 2020 | 50,000 EUR | -36.43 M EUR | -33.59 M EUR |
| 2021 | 10,000 EUR | -52.58 M EUR | -47 M EUR |
| 2022 | 0 EUR | -46.7 M EUR | -57.04 M EUR |
| 2023 | 30.06 M EUR | -26.78 M EUR | -39.7 M EUR |
| 2024e | 28.85 M EUR | -38.14 M EUR | -41.97 M EUR |
| 2025e | 17.79 M EUR | -48.96 M EUR | -49.17 M EUR |
| 2026e | 46.36 M EUR | -18.54 M EUR | -26.75 M EUR |
| 2027e | 30.12 M EUR | -38.38 M EUR | -43.27 M EUR |
| 2028e | 58.61 M EUR | -12.25 M EUR | -26.25 M EUR |
| 2029e | 159.4 M EUR | 0 EUR | 70.49 M EUR |
Nanobiotix stock margins FR0011341205 · A1J7EB
The Nanobiotix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nanobiotix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nanobiotix.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Nanobiotix's sales revenue. A higher gross margin percentage indicates that the Nanobiotix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Nanobiotix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Nanobiotix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nanobiotix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nanobiotix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nanobiotix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Nanobiotix Margin History
| Nanobiotix Gross margin | Nanobiotix Profit margin | Nanobiotix EBIT margin | Nanobiotix Profit margin |
|---|---|---|---|
| 2029e | 26,500 % | 0 % | 44.22 % |
| 2028e | 26,500 % | -20.91 % | -44.79 % |
| 2027e | 26,500 % | -127.43 % | -143.67 % |
| 2026e | 26,500 % | -39.99 % | -57.71 % |
| 2025e | 26,500 % | -275.24 % | -276.43 % |
| 2024e | 26,500 % | -132.19 % | -145.47 % |
| 2023 | 26,500 % | -89.09 % | -132.08 % |
| 2022 | 26,500 % | 0 % | 0 % |
| 2021 | 26,500 % | -525,790 % | -470,030 % |
| 2020 | 4,640 % | -72,856 % | -67,180 % |
| 2019 | 26,500 % | -68,792.65 % | -74,875 % |
| 2018 | 26,500 % | -25,919.83 % | -26,159.48 % |
| 2017 | 26,500 % | -10,026.59 % | -10,374.21 % |
| 2016 | 26,500 % | -1,402.65 % | -1,404.31 % |
| 2015 | 26,500 % | -6,455.39 % | -6,403.21 % |
| 2014 | 26,500 % | -994.29 % | -987.76 % |
| 2013 | 26,500 % | -4,544.44 % | -4,522.22 % |
| 2012 | 26,500 % | -7,357.14 % | -7,614.29 % |
| 2011 | 100 % | -384.56 % | -386.03 % |
| 2010 | 100 % | -362.83 % | -361.95 % |
| 2009 | 96.39 % | -54.15 % | -54.51 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2009 | 96.39 % | -54.15 % | -54.51 % |
| 2010 | 100 % | -362.83 % | -361.95 % |
| 2011 | 100 % | -384.56 % | -386.03 % |
| 2012 | 26,500 % | -7,357.14 % | -7,614.29 % |
| 2013 | 26,500 % | -4,544.44 % | -4,522.22 % |
| 2014 | 26,500 % | -994.29 % | -987.76 % |
| 2015 | 26,500 % | -6,455.39 % | -6,403.21 % |
| 2016 | 26,500 % | -1,402.65 % | -1,404.31 % |
| 2017 | 26,500 % | -10,026.59 % | -10,374.21 % |
| 2018 | 26,500 % | -25,919.83 % | -26,159.48 % |
| 2019 | 26,500 % | -68,792.65 % | -74,875 % |
| 2020 | 4,640 % | -72,856 % | -67,180 % |
| 2021 | 26,500 % | -525,790 % | -470,030 % |
| 2022 | 26,500 % | 0 % | 0 % |
| 2023 | 26,500 % | -89.09 % | -132.08 % |
| 2024e | 26,500 % | -132.19 % | -145.47 % |
| 2025e | 26,500 % | -275.24 % | -276.43 % |
| 2026e | 26,500 % | -39.99 % | -57.71 % |
| 2027e | 26,500 % | -127.43 % | -143.67 % |
| 2028e | 26,500 % | -20.91 % | -44.79 % |
| 2029e | 26,500 % | 0 % | 44.22 % |
Nanobiotix Aktienanalyse
What does Nanobiotix do?
Nanobiotix SA is a biotechnology company specializing in the development of nanoparticles used in cancer therapy to increase the effectiveness of radiation therapy. It was founded in 2003 in Paris, France by Dr. Laurent Lévy and his team. The company went public in 2012 and is currently listed on the Euronext Paris exchange. Nanobiotix's business model is based on the production and marketing of nanoparticles called NBTXR3, which enhance the effectiveness of radiation therapy. The company works with various partners to further develop its technology and explore new applications. Nanobiotix has two main divisions: one focused on developing nanoparticles to enhance radiation therapy for cancer, and another dedicated to using nanoparticles as drug carriers. Its flagship product, NBTXR3, is designed specifically for cancer therapy and has shown promising results. Nanobiotix is also working on combining NBTXR3 with immunotherapies to further improve cancer treatment. In summary, Nanobiotix is an innovative company specializing in the development of nanoparticles to enhance radiation therapy for cancer and improve patient treatment. Nanobiotix ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Nanobiotix's Sales Figures
The sales figures of Nanobiotix originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Nanobiotix’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Nanobiotix's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Nanobiotix’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Nanobiotix stock
How much was the turnover of the company Nanobiotix compared to the previous year?
The revenue of Nanobiotix has increased by -4.02% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Nanobiotix?
The revenue of Nanobiotix is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Nanobiotix measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Nanobiotix so important for investors?
The revenue of Nanobiotix is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Nanobiotix pay?
Over the past 12 months, Nanobiotix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nanobiotix is expected to pay a dividend of 0 EUR.
What is the dividend yield of Nanobiotix?
The current dividend yield of Nanobiotix is .
When does Nanobiotix pay dividends?
Nanobiotix pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Nanobiotix?
Nanobiotix paid dividends every year for the past 0 years.
What is the dividend of Nanobiotix?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Nanobiotix located?
Nanobiotix is assigned to the 'Health' sector.
Wann musste ich die Aktien von Nanobiotix kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Nanobiotix from 9/22/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.
When did Nanobiotix pay the last dividend?
The last dividend was paid out on 9/22/2024.
What was the dividend of Nanobiotix in the year 2023?
In the year 2023, Nanobiotix distributed 0 EUR as dividends.
In which currency does Nanobiotix pay out the dividend?
The dividends of Nanobiotix are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Nanobiotix stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Nanobiotix
Our stock analysis for Nanobiotix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nanobiotix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
